Suppliers and packagers for MORPHINE SULFATE

MORPHINE SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Elizabeth	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	079040	ANDA	Actavis Pharma, Inc.	0228-3090-11	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3090-11)	2014-02-04
Actavis Elizabeth	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	079040	ANDA	Actavis Pharma, Inc.	0228-3091-11	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3091-11)	2014-02-04
Actavis Elizabeth	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	079040	ANDA	Actavis Pharma, Inc.	0228-3092-11	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3092-11)	2014-02-04
Actavis Elizabeth	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	079040	ANDA	Actavis Pharma, Inc.	0228-3093-11	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3093-11)	2014-02-04
Actavis Elizabeth	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	079040	ANDA	Actavis Pharma, Inc.	0228-3116-11	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3116-11)	2014-02-04
Actavis Elizabeth	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	079040	ANDA	Actavis Pharma, Inc.	0228-3117-11	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0228-3117-11)	2014-02-04

Morphine Sulfate Drug Supply Chain Analysis

Last updated: February 19, 2026

Morphine sulfate, a critical opioid analgesic, relies on a complex global supply chain involving raw material sourcing, active pharmaceutical ingredient (API) manufacturing, and final drug product formulation. Key players are subject to stringent regulatory oversight from agencies like the U.S. Drug Enforcement Administration (DEA) and the U.S. Food and Drug Administration (FDA), as well as international bodies. Supply chain vulnerabilities, particularly concerning the availability of poppy-derived opiates, present ongoing challenges.

What are the Primary Sources for Morphine Sulfate API?

The primary source for morphine sulfate API is the opium poppy, Papaver somniferum. Cultivation of this plant is tightly controlled and concentrated in specific regions globally.

• Opium Gum Production: Opium gum, the latex extracted from the poppy seed pods, is the initial raw material containing morphine and codeine. Major opium-producing countries, subject to strict international controls under the United Nations Single Convention on Narcotic Drugs, include:
  • Australia: Known for high-yield poppy varieties and robust cultivation practices.
  • Turkey: A traditional producer of opium gum.
  • India: Significant producer with a long history of cultivation.
  • Spain: Cultivates poppies primarily for seed oil, but also for straw for alkaloids.
  • France: Cultivates poppies for straw.
• Alkaloid Extraction: Opium gum or poppy straw (the dried plant material after seed harvest) is processed to extract the principal alkaloids, including morphine. This extraction occurs in specialized facilities.
  • Australia is a dominant player in the extraction of alkaloids from Papaver somniferum straw, supplying a significant portion of the world's opiate raw material. Companies like TPI (Thepharmaceutical industry) are major extractors.
  • European Union countries, particularly Spain and France, also have facilities that process poppy straw.

The extracted morphine is then further processed into morphine sulfate API.

Who are the Key Manufacturers of Morphine Sulfate API?

API manufacturers transform the extracted morphine into the stable sulfate salt form suitable for pharmaceutical formulation. These manufacturers are highly regulated and often operate under strict quota systems.

• Major Global API Producers:
  • Mallinckrodt Pharmaceuticals (now part of McKesson): Historically a significant producer of opioid APIs in the U.S.
  • Pfizer Inc.: Manufactures opioid APIs, including morphine sulfate.
  • Actavis (now AbbVie): Has been involved in API production.
  • Noramco: A U.S.-based subsidiary of Johnson & Johnson, is a key API manufacturer, producing a range of controlled substances.
  • Sekem Pharma (Egypt): Engaged in API manufacturing.
  • Egyptian International Pharmaceutical Industries Co. (EIPICO - Egypt): Another significant Egyptian API producer.
  • Bavaria Solms (Germany): Operates within the opiate market.
  • TEVA Pharmaceutical Industries (Israel): Has had API manufacturing operations.

The selection of API manufacturers can be influenced by regulatory approvals, cost of production, and supply chain security.

What Companies Formulate Morphine Sulfate into Finished Dosage Forms?

Finished dosage form manufacturers purchase the morphine sulfate API and formulate it into various products, such as tablets, capsules, injectable solutions, and suppositories. This stage also involves significant regulatory compliance.

• Leading Formulators (North America):
  • AbbVie Inc. (through its acquisition of Allergan, which includes Actavis): Produces various opioid formulations.
  • Baxter International Inc.: A major supplier of injectable drugs, including parenteral morphine sulfate.
  • Fresenius Kabi: Another key player in injectable drug manufacturing.
  • Hikma Pharmaceuticals: Has a portfolio of pain management medications.
  • Insys Therapeutics (now defunct, but previously a player): Had focused on opioid products.
  • Teva Pharmaceutical Industries: Offers a range of generic and branded medications.
  • Mallinckrodt Pharmaceuticals: Continues to supply finished dosage forms.
• Leading Formulators (Europe):
  • B. Braun Melsungen AG: Manufactures parenteral nutrition and infusion therapy products, including opioid solutions.
  • Sanofi S.A.: Has a broad pharmaceutical portfolio that includes pain management.
  • Grünenthal Group: A pharmaceutical company with a focus on pain.
  • Takeda Pharmaceutical Company: Global presence in various therapeutic areas, including pain.
• Other Global Formulators: Companies in India, such as Sun Pharmaceutical Industries and Dr. Reddy's Laboratories, also manufacture and distribute morphine sulfate products.

These companies ensure compliance with Good Manufacturing Practices (GMP) and manage the complex distribution of controlled substances.

What are the Regulatory Hurdles and Controls on Morphine Sulfate Production?

The production and distribution of morphine sulfate are among the most tightly regulated pharmaceutical processes globally due to its potential for abuse and addiction.

• International Control:
  • United Nations Office on Drugs and Crime (UNODC): Administers the Single Convention on Narcotic Drugs, 1961, which mandates international cooperation and controls on the production, distribution, and use of opiates.
  • International Narcotics Control Board (INCB): Monitors and guides countries in implementing UN drug control conventions, including setting annual estimates and requirements for opiate cultivation and production.
• National Control (United States):
  • Drug Enforcement Administration (DEA): Regulates the manufacture, distribution, and possession of controlled substances.
    • Schedules: Morphine sulfate is classified as a Schedule II controlled substance under the Controlled Substances Act (CSA), indicating a high potential for abuse, dependence, and severe psychological or physical dependence.
    • Quotas: The DEA sets annual aggregate production quotas for Schedule II substances, limiting the total amount of morphine sulfate that can be manufactured in the U.S. each year. Manufacturers must apply for and receive individual manufacturing quotas.
    • Registration and Licensing: All entities involved in handling morphine sulfate (manufacturing, distributing, prescribing, dispensing) must be registered with the DEA.
    • Record Keeping and Reporting: Strict requirements are in place for tracking all quantities of morphine sulfate from raw material to finished product.
  • Food and Drug Administration (FDA): Oversees drug safety, efficacy, and manufacturing quality.
    • Good Manufacturing Practices (GMP): Manufacturers must adhere to FDA’s GMP regulations to ensure product quality and consistency.
    • Abbreviated New Drug Applications (ANDAs) and New Drug Applications (NDAs): Approval is required for generic and branded finished products.
• National Control (Other Countries): Similar regulatory bodies exist in other major markets, often mirroring the U.S. and international frameworks. Examples include the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the European Medicines Agency (EMA) in the EU.

The stringent regulatory environment necessitates significant investment in compliance infrastructure and can impact production volumes and lead times.

What are the Current Challenges and Risks in the Morphine Sulfate Supply Chain?

The morphine sulfate supply chain faces several persistent challenges that can affect availability and pricing.

• Raw Material Volatility:
  • Crop Dependency: Reliance on agricultural output makes the supply vulnerable to weather events, crop diseases, and political instability in growing regions.
  • Quota Limitations: International and national quotas on opium cultivation and processing can limit the volume of raw material available, leading to potential shortages.
  • Illegal Diversion: The potential for diversion of opium and its derivatives into illicit markets requires constant vigilance and robust security measures, sometimes leading to over-regulation that can impede legitimate supply.
• Manufacturing Bottlenecks:
  • DEA Quotas: Annual production quotas set by the DEA can constrain the output of API manufacturers, especially if demand exceeds allocated amounts.
  • GMP Compliance: Maintaining stringent GMP standards requires continuous investment and can lead to production halts if non-compliance issues arise.
  • Geopolitical Factors: Political instability or trade restrictions in countries where API manufacturing or raw material processing occurs can disrupt supply.
• Distribution and Security:
  • Controlled Substance Logistics: Transporting and storing controlled substances requires specialized security protocols and licensing, increasing logistical costs and complexity.
  • Diversion Prevention: Robust systems are needed to prevent diversion at every stage of the supply chain, from farm to pharmacy.
• Market Dynamics:
  • Pricing Fluctuations: The cost of raw materials and API can fluctuate based on supply availability and demand.
  • Generic Competition: The market for many morphine sulfate formulations is mature and highly competitive, characterized by price pressure.
  • Emergence of Alternatives: While morphine remains a cornerstone of severe pain management, research into non-opioid analgesics and alternative pain management strategies could, over the long term, impact demand for opioids.

Companies must maintain diversified sourcing strategies and robust risk management protocols to mitigate these challenges.

Key Takeaways

The morphine sulfate supply chain is characterized by its reliance on agricultural raw materials, highly specialized API manufacturers, and a fragmented global network of finished dosage form producers. Stringent international and national regulatory controls, primarily managed by entities such as the UNODC, INCB, DEA, and FDA, govern every stage of production and distribution. Key challenges include raw material volatility due to crop dependency and quota limitations, manufacturing bottlenecks influenced by production quotas and GMP compliance, and complex distribution requiring enhanced security. Companies operating within this sector must navigate these complexities through diversified sourcing, rigorous compliance, and proactive risk management to ensure a stable supply of this critical analgesic.

Frequently Asked Questions

1. How do DEA production quotas impact morphine sulfate availability?

DEA aggregate production quotas establish an annual limit on the total amount of Schedule II controlled substances, including morphine sulfate, that can be manufactured in the U.S. Manufacturers must apply for individual quotas, and if demand exceeds the allocated quota for a given year, it can directly lead to API or finished product shortages. This system is designed to prevent oversupply and diversion but can create supply chain inflexibility.

2. What is the primary difference between morphine API and a finished morphine sulfate drug product?

Morphine sulfate API (Active Pharmaceutical Ingredient) is the pure chemical compound that provides the pharmacological effect. It is the bulk substance manufactured by specialized chemical processors. A finished morphine sulfate drug product is the final dosage form (e.g., tablet, injection) that a patient receives. It is created by pharmaceutical companies that combine the API with excipients (inactive ingredients) under strict GMP conditions and package it for distribution.

3. Are there any synthetic alternatives to morphine sulfate that bypass poppy cultivation?

While research continues into non-opioid analgesics and pain management modalities, there are currently no widely adopted synthetic alternatives that directly replace morphine sulfate's pharmacological profile and clinical utility derived from natural opiates. Some synthetic opioids exist (e.g., fentanyl, oxycodone, hydromorphone), but these are also derived from opium alkaloids or related precursors and are also heavily controlled. True synthesis from basic chemical building blocks that replicate morphine's complex structure and function without relying on opiate precursors is a significant scientific challenge.

4. What are the main risks associated with the global sourcing of opium for morphine production?

The main risks associated with global opium sourcing include:

• Agricultural Volatility: Susceptibility to weather, pests, and plant diseases can impact yield and quality.
• Geopolitical Instability: Cultivation regions may be subject to political unrest, conflict, or changes in government policy that can disrupt legal production.
• Illegal Diversion: The inherent risk that raw opium or processed alkaloids could be diverted from legitimate channels into illicit drug manufacturing and trafficking.
• Regulatory Changes: Shifting international agreements or national cultivation policies can alter the availability and cost of raw materials.
• Ethical and Environmental Concerns: Issues related to labor practices, land use, and environmental impact in cultivation areas require careful management and oversight.

5. How has the opioid crisis affected the supply chain for legitimate medical use of morphine sulfate?

The opioid crisis has led to significantly increased scrutiny and regulatory control over all opioid products, including morphine sulfate. This includes tighter DEA quotas, more rigorous tracking and reporting requirements, and increased security measures throughout the supply chain. While intended to curb illicit use and diversion, these heightened controls can sometimes create administrative burdens and, in some instances, contribute to temporary supply chain disruptions if manufacturers struggle to meet new compliance demands or if quotas are set too restrictively for legitimate medical needs. Pharmaceutical companies must demonstrate a clear medical necessity and robust diversion prevention strategies to operate.

Citations

[1] United Nations Office on Drugs and Crime. (n.d.). The Single Convention on Narcotic Drugs, 1961. Retrieved from [UNODC Website] (Specific URL would depend on direct access to their published conventions page) [2] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from DEA Website. [3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from FDA Website. [4] International Narcotics Control Board. (n.d.). Role of the INCB. Retrieved from INCB Website. [5] McKesson Corporation. (n.d.). About McKesson. Retrieved from McKesson Website. (Implied through acquisition of Mallinckrodt's relevant business segments). [6] Pfizer Inc. (n.d.). Product Information. Retrieved from Pfizer Website. (General reference to their pharmaceutical manufacturing capabilities). [7] AbbVie Inc. (n.d.). Our Products. Retrieved from AbbVie Website. (General reference to their portfolio which includes pain management). [8] Baxter International Inc. (n.d.). Product Portfolio. Retrieved from Baxter Website. (General reference to their injectable drug offerings). [9] Fresenius Kabi. (n.d.). Product Range. Retrieved from Fresenius Kabi Website. (General reference to their infusion and injectable products). [10] Hikma Pharmaceuticals. (n.d.). Our Products. Retrieved from Hikma Pharmaceuticals Website. (General reference to their pain management medications). [11] Teva Pharmaceutical Industries Ltd. (n.d.). Our Products. Retrieved from Teva Website. (General reference to their generic and branded medications). [12] B. Braun Melsungen AG. (n.d.). Product Categories. Retrieved from B. Braun Website. (General reference to infusion therapy products). [13] Sanofi S.A. (n.d.). Therapeutic Areas. Retrieved from Sanofi Website. (General reference to their involvement in pain management). [14] Grünenthal Group. (n.d.). Therapeutic Focus. Retrieved from Grünenthal Website. (General reference to their focus on pain). [15] Sun Pharmaceutical Industries Ltd. (n.d.). Product Portfolio. Retrieved from Sun Pharma Website. (General reference to their manufacturing capabilities). [16] Dr. Reddy's Laboratories. (n.d.). Product Offerings. Retrieved from Dr. Reddy's Website. (General reference to their pharmaceutical manufacturing).